Osteoporosis

What is Osteoporosis?

Osteoporosis is a bone disease characterized by decreased bone density and strength, which makes bones more fragile and prone to fractures. It often progresses without symptoms until a fracture occurs.

Causes of Osteoporosis

Risk Factors

Symptoms of Osteoporosis

Osteoporosis is often called a “silent disease” because bone loss occurs without symptoms. When symptoms do appear, they may include:

Diagnosis

Prevention Strategies

Treatment Options

Complications of Osteoporosis


9. References & Research

Historical Background

The term "osteoporosis" was coined by French pathologist Jean Lobstein in 1835, meaning "porous bone." Fuller Albright in the 1940s established the link between estrogen deficiency and postmenopausal bone loss, laying the groundwork for modern understanding of the disease. The development of dual-energy X-ray absorptiometry (DEXA) in the 1980s revolutionized diagnosis and screening.

Key Research Papers

  1. Black DM, Rosen CJ. Postmenopausal Osteoporosis. New England Journal of Medicine. 2016;374(3):254-262.
  2. Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis. 2017;12:43.
  3. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. The Lancet. 2011;377(9773):1276-1287.
  4. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX). JAMA. 2006;296(24):2927-2938.
  5. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis (FREEDOM trial). New England Journal of Medicine. 2009;361(8):756-765.
  6. Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1595-1622.
  7. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis (ARCH trial). New England Journal of Medicine. 2017;377(15):1417-1427.
  8. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women (WHI). JAMA. 2002;288(3):321-333.
  9. Compston JE, McClung MR, Leslie WD. Osteoporosis. The Lancet. 2019;393(10169):364-376.
  10. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine. 2001;344(19):1434-1441.
  11. Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International. 2019;30(1):3-44.
  12. Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. The Lancet Diabetes & Endocrinology. 2017;5(11):898-907.

Back to Table of Contents